Clozapine for the treatment of immunoglobulin-driven B cell disease

摘要

The present invention is acceptable as the compounds clozapine and its major metabolite norclozapine, their prodrugs, and their pharmaceutically for use in the treatment or prevention of pathogenic immunoglobulin-driven B cell diseases associated with T cell components. With respect to possible salts and metabolites. The present invention also provides a pharmaceutical composition containing such a compound. [Selection diagram] None